RESEARCH: NICLOSAMIDE in CANCER and Other Diseases - 2025 Review Paper From Henan, China

Key Takeaways

• Niclosamide shows activity against multiple solid tumor types
• Phase II trials report 15% response rate in pancreatic cancer
• Oral formulation improves bioavailability over traditional tablets
• Combination with immune checkpoint inhibitors enhances tumor regression
• Safety profile remains favorable with mild gastrointestinal side effects

Pulse Analysis

The resurgence of niclosamide in oncology stems from its ability to disrupt several cancer‑driving pathways, including Wnt/β‑catenin, STAT3, and mitochondrial respiration. Researchers in Henan synthesized data from cell‑line screens and animal models, revealing consistent growth inhibition across diverse tumor histologies. By targeting metabolic vulnerabilities, niclosamide can sensitize cancer cells to standard chemotherapies, a finding that aligns with the broader trend of drug repurposing to shorten development timelines and lower costs.

Clinical translation has been hampered historically by poor oral absorption and rapid clearance. Recent formulation breakthroughs—such as nanoparticle encapsulation and pro‑drug derivatives—have increased systemic exposure by up to threefold, enabling therapeutic plasma concentrations in early‑phase trials. In a Phase II study of advanced pancreatic adenocarcinoma, niclosamide achieved a 15% objective response rate and disease stabilization in an additional 30% of patients, with only mild nausea and diarrhea reported. These outcomes suggest that, when paired with existing regimens, niclosamide can augment efficacy without adding substantial toxicity.

Looking ahead, the most promising avenue appears to be combination therapy with immune checkpoint inhibitors. Pre‑clinical models demonstrate that niclosamide can modulate the tumor microenvironment, reducing immunosuppressive myeloid cells and enhancing T‑cell infiltration. Ongoing trials are evaluating niclosamide alongside pembrolizumab in metastatic melanoma and non‑small cell lung cancer, aiming to capitalize on synergistic anti‑tumor effects. If successful, niclosamide could become a cost‑effective, orally delivered adjunct that broadens the therapeutic arsenal against refractory cancers.